ENTITY
Bristol-Myers Squibb

Bristol-Myers Squibb (BMY UN)

3
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol Myers Squibb focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
bullishPeptidream Inc
01 May 2024 22:55

Peptidream (4587 JP): Steadily Riding the Next Wave of Drug Discovery

Peptidream got nod for first human trial for radiopharma targeting renal cell carcinoma. Expanded peptide discovery collaboration with Novartis...

Logo
383 Views
Share
08 Mar 2024 22:58

Karuna Therapeutics: Is The Bidding Battle Underway?

I see a strong wave of M&A activity in neuropsychiatry space and think the risk/reward of owning KRTX shares is favorable despite the substantial...

Logo
478 Views
Share
07 Mar 2024 18:37

Karuna Therapeutics (KRTX US): BMS Acquisition Offers Decent Short-Term Trading Opportunity

​BMS is acquiring Karuna Therapeutics for $330/share in cash, with the deal expected to close in 1H24. Current market price of Karuna shares...

Logo
378 Views
Share
28 Feb 2024 02:00

Bristol-Myers Squibb: The Ongoing Growth Story Of Each Of Its Core Drugs! - Major Drivers

Bristol-Myers Squibb (BMS) reported a strong fourth quarter for 2023 with sales momentum in both their established and new product portfolios,...

Logo
277 Views
Share
bearishOrion Corp
17 Jan 2024 05:12

Orion Corp: Concerns About Diversification into LegoChem Bioscience

Orion Corp's investment in LegoChem Bio raises concerns about diversification into risky biotech business. Investors would rather have Orion Corp...

Logo
480 Views
Share
x